Development of an Assay Suitable for High-Throughput Screening to Measure Matrix Metalloprotease Activity

Assay and Drug Development Technologies

Volumn 1, Issue 3, 2003, Pages 425-433

  Peppard, Jane ^a   Pham, Quynhchi ^a   Clark, Ambereen ^a   Farley, David ^a   Sakane, Yumi ^a   Graves, Robert ^b   George, Jeanette ^c   Norey, Christopher ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Amersham Biosciences   (United States)

^c GENERAL ELECTRIC COMPANY   (United States)

Author keywords

4 aminophenylmercuric acid; absolute fluorescence units; AFU; APMA; CCD; charge coupled device; coefficient of variation; CV,; dimethyl sulfoxide; DMSO; matrix metalloprotease; MMP; relative fluorescence units; RFU; room temperature; RT

Indexed keywords

COLLAGENASE 3; DIMETHYL SULFOXIDE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; PEPTIDE; PROTEIN PLGLAARK; STROMELYSIN; UNCLASSIFIED DRUG; COLLAGENASE; ENZYME INHIBITOR; FLUORESCENT DYE; METALLOPROTEINASE; MMP13 PROTEIN, HUMAN; OLIGOPEPTIDE; PROLYL LEUCYL GLYCYL LEUCYL ALANYL ALANYL ARGINYL LYSINE; PROLYL-LEUCYL-GLYCYL-LEUCYL-ALANYL-ALANYL-ARGINYL-LYSINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; IC50; IMAGING SYSTEM; SPECTROPHOTOMETER; BINDING SITE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYME SPECIFICITY; REPRODUCIBILITY; TIME;

BINDING SITES; COLLAGENASES; DIMETHYL SULFOXIDE; ENZYME INHIBITORS; FLUORESCENT DYES; HUMANS; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; OLIGOPEPTIDES; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 3142730512     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/154065803322163731     Document Type: Article

References (20)

1. Nelson AR, Fingleton B, Rothenburg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1144.
2. McCawley LJ, Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-543.
3. Hooper NM, Karran EH, Turner AJ: Membrane protein secretases. Biochem J 1997;321:265-274.
4. Herren B: ADAM-mediated shedding and adhesion: a vascular perspective. News Physiol Sci 2002;17:73-76.
5. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-185.
6. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-1922.
7. Nagase H, Fields CG, Fields J: Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin-1 (matrix metalloproteinase-3). J Biol Chem 1994;269:20952-20962.
8. Lauer-Fields JL, Tuzinski KA, Shimokawa K, Nagase H, Fields GB: Hydrolysis of triple-helix collagen peptide models by matrix metalloproteinases. J Biol Chem 2000;275: 13282-13290.
9. Deng SJ, Bickett DM, Mitchell JL, Lambert MH, Blackburn RK, Carter HL, Neugebauer J, Pahel G, Weiner MP, Moss ML: Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 2000;275:1422-1427.
10. Knight CG, Willenbrock F, Murphy G: A novel coumarinlabelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992;296:263-272.
11. Mujumdar RB, Ernst LA, Mujumdar SR, Lewis CJ, Waggoner AS: Cyanine dye labeling reagents: sulfoindocyanine succinimidyl esters. Bioconjug Chem 1993;4:105-111.
12. Mujumdar SR, Mujumdar RB, Grant CM, Waggoner AS: Cyanine-labeling reagents: sulfobenzindocyanine succinimidyl esters. Bioconjug Chem 1996;7:356-362.
13. Fowler A, Davies I, Norey C: A multi-modality assay platform for ultra-high throughput screening. Curr Pharm Biotechnol 2000;1:265-281.
14. George J, Ward RJ, Teear ML, Norey CG, Burns DD: Evaluation of an imaging platform during the development of a FRET protease assay. J Biomol Screen 2003;8:72-80.
15. Turconni S, Shea K, Ashman S, Fantom K, Earnshaw DL, Bingham RP, Haupts UM, Brown MJB, Pope AJ: Real experiences of uHTS: a prototypic 1536-well fluorescence anisotropy-based uHTS screen and application to well- level quality control procedures. J Biomol Screen 2001;6:275-290.
16. Sorg G, Schubert HD, Buttner FH, Heilker R: Automated high throughput screening for serine kinase inhibitors using a LEADseeker scintillation proximity assay in the 1536-well format. J Biomol Screen 2002;7:11-19.
17. Kariv I, Cao H, Marvil PD, Bobkova EV, Bukhtiyarov YE, Yan YP, Patel U, Coudurier L, Chung TDY, Oldenburg KR: Identification of inhibitors of bacterial transcription/translation machinery utilizing a miniaturized 1536-well format screen. J Biomol Screen 2001;6:233-243.
18. Abriola L, Chin M, Fuerst P, Schweitzer R, Sills M: Digital imaging as a detection method for a fluorescent protease assay in 96-well and miniaturized assay plate formats. J Biomol Screen 1999;4:121-127.
19. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V, Parker DT: Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromyelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40:2525-2532.
20. Doughty JR, Goldberg RL, Ganu V, Melton RA, Hu SI, Di Pasquale G: A stromelysin assay for the assessment of metalloprotease inhibitors on human aggregated proteoglycan. Agents Actions 1993;39:C151-C153.